Chronic Kidney Disease
Conditions
Keywords
OJR520, safety and tolerability, PK, PD, healthy volunteers, first in human, chronic kidney disease
Brief summary
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Detailed description
This is a three-part randomized, participant- and investigator blinded, placebo-controlled, multi-center, sequential study: single ascending dose (SAD) in healthy volunteers (HV), SAD in participants with chronic kidney disease (CKD) or diabetic chronic kidney disease (DKD) and multiple ascending dose (MAD) in participants with CKD or DKD.
Interventions
DRUGOJR520
Participants will receive OJR520 in different dose levels.
OTHERPlacebo
Participants will receive OJR520 matching placebo.
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Able to provide written informed consent before any assessment is performed. Part A (HV): • Healthy male and female participants in good health as determined by past medical history, physical examination, vital signs, 12-lead ECG, and laboratory tests at screening and baseline within the normal range. Parts B \& C (CKD) • Male and female participants 18 to 65 years of age.
Exclusion criteria
* Women of childbearing potential. * Sexually active males unwilling to use contraception. Part A (HV): * Clinically significant abnormal blood pressure, defined as SBP \<90 mmHg or \>140 mmHg or DBP \<55 mmHg or \>95 mmHg. * Abnormal resting HR, defined as \<45 bpm or \>90 bpm. Part B \& C (CKD) * History of, or currently active, significant illness or medical disorders including, but not limited to, cancer (except for non-melanoma skin cancer), heart failure NYHA III-IV, heart rhythm abnormalities (e.g., atrial fibrillation, sick sinus syndrome, permanent pacemaker), CKD due to autoimmune disease, kidney transplant, dialysis or any other disease the investigator believes may preclude the participant from participating in the this study. * Clinically significant aortic stenosis or mitral insufficiency as identified via echocardiography. * History of myocardial infarction (MI), stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or transient ischemic attack (TIA). Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs) | From Day 1 (Part A) until Day 71 (Part C) | Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Observed Blood Concentrations (Cmax) | From pre-dose Day 1 (Part A) until Day 71 (Part C) | Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1). |
| Time to reach maximum plasma concentration (Tmax) | From pre-dose Day 1 (Part A) until Day 71 (Part C) | Tmax is the time to reach maximum (peak) drug concentration after single-dose administration (time). |
| Area under plasma concentration-time curve (AUClast) | From pre-dose Day 1 (Part A) until Day 71 (Part C) | AUClast is the area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (tlast). |
| Area under the plasma concentration-time curve (AUC[0-inf]) | From pre-dose Day 1 (Part A) until Day 71 (Part C) | The AUC\[0-inf\] from time zero extrapolated to infinity (mass x time x volume-1). |
| Terminal elimination half-life (T1/2) | From pre-dose Day 1 (Part A) until Day 71 (Part C) | T1/2 is the elimination half-life associated with the terminal slope. |
| Apparent plasma clearance (CL/F) | From pre-dose Day 1 (Part A) until Day 71 (Part C) | CL/F is the apparent total body clearance of drug from plasma following extravascular administration. |
| Apparent volume of distribution during terminal elimination phase (Vz/F) | From pre-dose Day 1 (Part A) until Day 71 (Part C) | Vz/F is the apparent volume of distribution during terminal elimination phase following extravascular administration. |
| Drug accumulation ratio (Racc) | Part C: From pre-dose Day 1 until Day 71 | The ratio of accumulation of drug between the first and last dose, only for MAD part of the study. |
| Area under plasma concentration-time curve (AUCtau) | Part C: From pre-dose Day 1 until Day 71 | The AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1) only for MAD part of the study. |
Countries
Germany, United States
Contacts
CONTACTNovartis Pharmaceuticals
Outcome results
None listed